JP2015520175A5 - - Google Patents

Download PDF

Info

Publication number
JP2015520175A5
JP2015520175A5 JP2015515352A JP2015515352A JP2015520175A5 JP 2015520175 A5 JP2015520175 A5 JP 2015520175A5 JP 2015515352 A JP2015515352 A JP 2015515352A JP 2015515352 A JP2015515352 A JP 2015515352A JP 2015520175 A5 JP2015520175 A5 JP 2015520175A5
Authority
JP
Japan
Prior art keywords
antigen
antagonist
polynucleotide
subject
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015515352A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015520175A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2013/000589 external-priority patent/WO2013181696A1/en
Publication of JP2015520175A publication Critical patent/JP2015520175A/ja
Publication of JP2015520175A5 publication Critical patent/JP2015520175A5/ja
Pending legal-status Critical Current

Links

JP2015515352A 2012-06-05 2013-06-05 インターロイキン−4アンタゴニストを伴うワクチン接種 Pending JP2015520175A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2012902345A AU2012902345A0 (en) 2012-06-05 Vaccination with Interleukin-4 Antagonists
AU2012902345 2012-06-05
PCT/AU2013/000589 WO2013181696A1 (en) 2012-06-05 2013-06-05 Vaccination with interleukin-4 antagonists

Publications (2)

Publication Number Publication Date
JP2015520175A JP2015520175A (ja) 2015-07-16
JP2015520175A5 true JP2015520175A5 (https=) 2016-07-21

Family

ID=49711200

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015515352A Pending JP2015520175A (ja) 2012-06-05 2013-06-05 インターロイキン−4アンタゴニストを伴うワクチン接種

Country Status (15)

Country Link
US (1) US20150150963A1 (https=)
EP (2) EP3530283A1 (https=)
JP (1) JP2015520175A (https=)
KR (1) KR20150021088A (https=)
CN (1) CN104717971A (https=)
AU (1) AU2013271338B2 (https=)
BR (1) BR112014030436A2 (https=)
CA (1) CA2875683A1 (https=)
HK (1) HK1203358A1 (https=)
IL (1) IL236092A0 (https=)
IN (1) IN2014DN10408A (https=)
NZ (1) NZ702721A (https=)
SG (1) SG11201408101TA (https=)
WO (1) WO2013181696A1 (https=)
ZA (1) ZA201409076B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017220184B2 (en) * 2016-02-19 2024-04-18 Regeneron Pharmaceuticals, Inc. Methods for enhancing efficacy of a vaccine by administering an IL-4R antagonist
CN113527485B (zh) * 2020-04-17 2024-11-15 湖南麦济生物技术股份有限公司 抗人白细胞介素-4受体α抗体及其制备方法和应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
JP3282188B2 (ja) 1991-06-27 2002-05-13 日本電気株式会社 半導体メモリ装置
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
AU691175B2 (en) 1993-03-31 1998-05-14 Nippon Zeon Co., Ltd. Novel polypeptide, DNA coding for said polypeptide, recombinant vector containing said DNA, recombinant virus prepared using said vector, and use thereof
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
DK0690732T3 (da) 1994-01-21 2003-05-19 Powderject Vaccines Inc Gasdrevet genindførselsinstrument
GB9502879D0 (en) 1995-02-14 1995-04-05 Oxford Biosciences Ltd Particle delivery
US6265387B1 (en) 1995-10-11 2001-07-24 Mirus, Inc. Process of delivering naked DNA into a hepatocyte via bile duct
US6458560B1 (en) 1996-04-05 2002-10-01 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
IL127692A0 (en) 1996-07-01 1999-10-28 Rhone Poulenc Rorer Sa Method for producing recombinant adenovirus
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
NZ505325A (en) 1997-12-23 2003-07-25 Crucell Holland B Adeno-associated virus and adenovirus chimeric recombinant viruses useful for the integration of foreign genetic information into the chromosomal dna of target cells
US6972013B1 (en) 1998-07-13 2005-12-06 Genetronics, Inc. Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation
US7922709B2 (en) 1998-07-13 2011-04-12 Genetronics, Inc. Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation
US7608273B2 (en) 1998-08-12 2009-10-27 University Of Western Ontario Recombinant lentivirus encoding modified GP 120 signal sequences
AT408615B (de) 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
JP4693244B2 (ja) 1999-03-18 2011-06-01 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 組換えアデノ随伴ウイルスのヘルパー無しの生産のための組成物および方法
ATE528406T1 (de) 1999-04-29 2011-10-15 Gbp Ip Llc Verfahren und mittel zur herstellung von sicheren,rekombinanten lentivirusvektoren mit hohem titer
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
AU2001257611A1 (en) 2000-04-28 2001-11-12 Avigen, Inc. Polynucleotides for use in recombinant adeno-associated virus virion production
ATE315660T1 (de) 2002-05-16 2006-02-15 Bavarian Nordic As Intergene regionen als insertionsstellen im genom von modifiziertem vaccinia virus ankara (mva)
AU2003263653A1 (en) 2002-09-27 2004-04-19 Daewoong Co., Ltd. A vaccine enhancing the protective immunity to hepatitis c virus using plasmid dna and recombinant adenovirus
US8287879B2 (en) * 2003-10-16 2012-10-16 The Regents Of The University Of California Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use
US20080131940A1 (en) 2004-06-25 2008-06-05 Robert Chiu Target Cell-Specific Short Interfering Rna and Methods of Use Thereof
WO2006135436A2 (en) 2004-10-22 2006-12-21 University Of Florida Research Foundation, Inc. Inhibition of gene expression and therapeutic uses thereof
US7541046B1 (en) 2005-01-04 2009-06-02 Gp Medical, Inc. Nanoparticles for protein drug delivery
US7611690B2 (en) 2005-01-04 2009-11-03 Gp Medical, Inc. Nanoparticles for protein drug delivery
US8048404B1 (en) 2005-01-04 2011-11-01 Gp Medical, Inc. Pharmaceutical composition of nanoparticles for protein drug delivery
CA2605924A1 (en) 2005-04-24 2006-11-02 Acambis Inc. Recombinant flavivirus vaccines
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
JP2009525267A (ja) * 2006-01-11 2009-07-09 アエロヴァンス インコーポレイティッド ヒトおよび非ヒト霊長類において喘息を処置するための方法および組成物
AR066240A1 (es) * 2007-04-23 2009-08-05 Wyeth Corp Metodos y composiciones para tratar y monitorear el tratamiento de trastornos asociados con il-13
US20120088814A1 (en) * 2009-03-31 2012-04-12 Isis Pharmaceuticals, Inc. Methods of modulating an immune response to a viral infection
WO2011003138A1 (en) * 2009-07-06 2011-01-13 The Australian National University Immunomodulating compositions comprising interleukin 13 inhibitors and uses therefor

Similar Documents

Publication Publication Date Title
JP2016074727A5 (https=)
Sun et al. Mucosal priming with a replicating-vaccinia virus-based vaccine elicits protective immunity to simian immunodeficiency virus challenge in rhesus monkeys
García-Martínez et al. Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy
RU2015155821A (ru) Вакцины против малярии
JP2020528911A5 (https=)
JP2015506179A5 (https=)
JP2019526580A5 (https=)
JP2016527286A5 (https=)
BR112018068748A2 (pt) composto, composição farmacêutica e de vacina, métodos para indução ou promoção de uma resposta imunológica, para tratamento de câncer, de doenças infecciosas, de distúrbios imunológicos e de doenças imunológicas e para tratamento ou prevenção de uma doença, e, uso de um composto
PH12018502684B1 (en) A rationally developed african swine fever attenuated virus strain protects against challenge with parental virus georgia 2007 isolate
RU2015132962A (ru) Иммуногенные композиции на основе вируса гриппа и их применение
JP2016516723A5 (https=)
JP2017523187A5 (https=)
JP2015529676A5 (https=)
JP2017501695A5 (https=)
CN111655281A (zh) 用于结核病的含环二核苷酸佐剂的疫苗的鼻内递送
BR112016013804A2 (pt) imunoterapia de câncer distribuindo antígenos mhc de classe ii usando um replicon de vlp
JP2015512866A5 (https=)
JP2012087150A5 (https=)
JP2015533376A5 (https=)
JP2017538680A5 (https=)
JP2011041578A5 (https=)
Viegas et al. Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design
JP2015514132A5 (https=)
JP2008543890A5 (https=)